SS47

Cat. No.:	HY-146231
CAS No.:	2636072-62-1
Molecular Formula:	$C_{49}H_{56}N_6O_{12}S$
Molecular Weight:	953.07
Target:	PROTACs; MAP4K
Pathway:	PROTAC; MAPK/ERK Pathway
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	SS47, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the antitumor efficacy[1].
IC_{50} & Target	HPK1
In Vitro	SS47 (100 nM, 24 h) has antitumor effect in CAR-T cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	SS47 (10 mg/kg, Subcutaneous injection, once a day for 10 days from day 5) can degrade HPK1 in 4T-1 tumor-bearing mice[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	4T-1 tumor-bearing mice[1]
Dosage:	10 mg/kg
Administration:	Subcutaneous injection (s.c.)
Result:	Exerted protea-some-mediated HPK1 degradation within 48 h.

REFERENCES

[1]. Si J, et al. Hematopoietic progenitor kinase1 (HPK1) mediates T cell dysfunction and is a druggable target for T cell-based immunotherapies [J]. Cancer Cell, 2020, 38(4): 551-566. e11.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA